Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
CAMBRIDGE, Mass., March 10, 2016 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that it will host its fourth quarter and full year 2015 investor update call before the open of the U.S. financial markets on Thursday, March 17, 2016. Voyager management will host a conference call and live audio webcast at 8:30 a.m. ET the same day.
The live call may be accessed by dialing (877) 489-6517 for domestic callers or +1 (929) 387-3945 for international callers, and referencing conference ID number 51816666. A live audio webcast of the conference call will be available online from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease and spinal muscular atrophy (SMA). Voyager has broad strategic collaborations with Genzyme Corporation, a Sanofi company, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
Contact: Investor Relations: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 [email protected] Media: Katie Engleman Pure Communications, Inc. 910-509-3977 [email protected]
